Program
Anti-nectin-4/CD28 Bispecific Antibody RNDO-564
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Rondo Therapeutics.
Furthest: phase 1, since Oct 14, 20251 company-led study, 1 open or runningNext primary completion: Feb 28, 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Rondo Therapeutics | 11 open or running | phase 1since Oct 14, 2025 | Oct 14, 2025 | Feb 28, 2029phase 1 · NCT07218003 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 14, 2025First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07218003 · 149 planned · United States
Ahead
- Feb 28, 2029Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07218003
TargetBeta
“An immunoglobulin G (IgG)-like human tumor-targeted co-stimulatory bispecific antibody directed against the tumor-associated antigen (TAA) nectin-4 (PVRL4) and the co-stimulatory T-cell surface glycoprotein CD28, ”NCIt, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07218003Carcinoma, Non-Small-Cell Lung · United States | 1 | By invitation | Feb 28, 2029 | 149 |
How it is read
Names in the registry
- “RNDO-564”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.